Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21084352 | 0.86 | MAPK14 (0.50) | MAPK14ALOX5KDM4EMAPTHPGD | |
| SCHEMBL19933873 | 0.85 | MAPK14 (0.45) | MAPK14ALOX5HSP90AA1MAPK1 | |
| SCHEMBL19933952 | 0.84 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL19933816 | 0.84 | — | — | |
| SCHEMBL19933977 | 0.83 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL19933882 | 0.83 | MAPK14 (0.44) | MAPK14 | |
| SCHEMBL19933956 | 0.82 | MAPK14 (0.45) | MAPK14 | |
| SCHEMBL19933944 | 0.80 | HSP90AA1 (0.41) | HSP90AA1 | |
| SCHEMBL19933745 | 0.78 | — | — | |
| SCHEMBL19933823 | 0.78 | KDM4E (0.43) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793544-B2 | Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-10-06 | — | — | US | disclosed |
| US-20190202804-A1 | DISUBSTITUTED AND TRISUBSTITUTED 1,2,3-TRIAZOLES AS WNT INHIBITORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2019-07-04 | — | — | US | disclosed |
| WO-2018045182-A1 | DISUBSTITUTED AND TRISUBTITUTED 1,2,3-TRIAZOLES AS WNT INHIBITORS | THE BOARD OF REGENTS OF HTE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202804-A1 | DISUBSTITUTED AND TRISUBSTITUTED 1,2,3-TRIAZOLES AS WNT INHIBITORS | WNT1, WNT3, WNT3A | MAPK14 967/4885ALOX5 1347/4885HSP90AA1 3184/4885 |
| US-10793544-B2 | Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors | WNT1, WNT3, WNT3A | MAPK14 967/4885ALOX5 1347/4885HSP90AA1 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.